BioCentury
ARTICLE | Company News

Senior FDA official to head government affairs at CRISPR Therapeutics

January 9, 2019 7:41 PM UTC

John Martin, principal associate commissioner for legislative affairs at FDA, is leaving the agency and joining CRISPR Therapeutics AG (NASDAQ:CRSP) as head of government affairs.

Martin, who joined FDA in 2017, led the agency's negotiation with Congress over reauthorization of user fees, and supported FDA’s writing of draft legislation that seeks to revamp regulation of diagnostics, including laboratory developed tests (see “Debating Diagnostics”)...